# Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct07074353/  
OnCo record `nct07074353` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Zhejiang Cancer Hospital, not yet recruiting.

## Summary

Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT07074353 by Zhejiang Cancer Hospital, with a registry enrolment figure of 360 participants, started 2025-07-20 and due to reach its primary completion in 2028-04-01. Interventions recorded: NALIRI; LCRT; FOLFOX. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Complete Response rate（CR）. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: CinClare-2
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07074353
- Phase: 3
- Setting: A Randomized, Multicenter Clinical Study of Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
- Sponsor: Zhejiang Cancer Hospital
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT07074353: https://clinicaltrials.gov/study/NCT07074353

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07074353.json